<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012102</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 200032-001</org_study_id>
    <nct_id>NCT01012102</nct_id>
  </id_info>
  <brief_title>EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>An Open Label, Parallel Group, Randomized Phase I Study of Biological Activity, Safety, Tolerability, and Clinical Activity of Different Dose Levels of EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare 3 doses of EMD 640744 administered by subcutaneous injection in combination with&#xD;
      Montanide® ISA 51 VG with regard to immunological efficacy.&#xD;
&#xD;
      The primary target variable is the immune response as assessed by ELISPOT before and until&#xD;
      week 17 after vaccination with EMD 640744 in Montanide® ISA 51 VG.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare 3 doses of EMD 640744 administered by subcutaneous injection in combination with Montanide® ISA 51 VG with regard to immunological efficacy</measure>
    <time_frame>1-4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of different doses of EMD 640744 in Montanide® ISA 51 VG in terms of laboratory parameters and adverse event profile.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the clinical efficacy in terms of the overall response, progression-free survival time, and survival time.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EMD 640744 30μg and Montanide® ISA 51 VG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EMD 640744 100μg and Montanide® ISA 51 VG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EMD 640744 300μg and Montanide® ISA 51 VG</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EMD 640744</intervention_name>
    <description>EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EMD 640744</intervention_name>
    <description>EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EMD 640744</intervention_name>
    <description>EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Montanide ISA 51 VG</intervention_name>
    <description>Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Montanide ISA 51 VG</intervention_name>
    <description>Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Montanide ISA 51 VG</intervention_name>
    <description>Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects ≥18 years of age&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Histologically or cytologically documented metastatic or locally advanced&#xD;
             survivin-expressing solid tumor for which no established therapy exists&#xD;
&#xD;
          -  Disease must be measurable by RECIST criteria or evaluable by clinical, radiographic,&#xD;
             or laboratory criteria established for the given tumor entity&#xD;
&#xD;
          -  Expressing at least one of the following HLA alleles:HLA-A1,-A2,-A3,-A24, and -B7&#xD;
             assessed by HLAgenotyping&#xD;
&#xD;
          -  ECOG performance status of ≤1, estimated life expectancy of at least 3 months&#xD;
&#xD;
          -  Adequate hematological function defined by WBC ≥3 x 10x9/L, lymphocyte count ≥0.5 x&#xD;
             10x9/L, hemoglobin ≥10 g/dL, platelet count ≥100 x 10x9/L&#xD;
&#xD;
          -  Adequate blood coagulation parameters defined as aPTT and INR ≤ 1.5 x ULN&#xD;
&#xD;
          -  Adequate renal function defined by a serum creatinine ≤2 x ULN&#xD;
&#xD;
          -  Adequate hepatic function defined by total bilirubin ≤2 x ULN and AST and ALT levels&#xD;
             ≤2.5 x ULN (in subjects with liver metastases ≤5 x ULN)&#xD;
&#xD;
          -  Effective contraception for female and male subjects if the risk of conception exists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment in another clinical study within the past 30 days prior to the first&#xD;
             administration of study treatment&#xD;
&#xD;
          -  Previous treatment with an investigational anticancer vaccine&#xD;
&#xD;
          -  Requirement of concurrent treatment with a nonpermitted drug&#xD;
&#xD;
          -  Active significant autoimmune disease (with the exception of vitiligo)&#xD;
&#xD;
          -  Receipt of allogeneic stem cell transplantation&#xD;
&#xD;
          -  Significant acute or chronic infections (e.g. viral hepatitis, HIV)&#xD;
&#xD;
          -  Primary brain tumors and brain metastases (with the exception of brain metastases that&#xD;
             are stable after irradiation or surgically resected brain metastases if subjects have&#xD;
             been asymptomatic for ≥6 months)&#xD;
&#xD;
          -  Rapidly progressive disease (e.g. tumor lysis syndrome)&#xD;
&#xD;
          -  Radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy), immunotherapy&#xD;
             or any investigational drug within 30 days before the start of study treatment&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Active drug or alcohol abuse&#xD;
&#xD;
          -  Known hypersensitivity to the study treatment or any of its components&#xD;
&#xD;
          -  Any significant disease that, in the Investigator's opinion, should exclude the&#xD;
             subject from the study; for questions about this criterion, the Investigator should&#xD;
             contact the sponsor.&#xD;
&#xD;
          -  Persisting toxicity related to prior therapy ≥grade 2 National Cancer Institute-Common&#xD;
             Terminology Criteria For Adverse Events version 3.0&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens-Peter Marschner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt</affiliation>
  </overall_official>
  <results_reference>
    <citation>Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother. 2014 Apr;63(4):381-94. doi: 10.1007/s00262-013-1516-5. Epub 2014 Feb 2.</citation>
    <PMID>24487961</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>October 20, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EMD 640744</keyword>
  <keyword>Montanide</keyword>
  <keyword>Advanced solid tumours</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

